Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th
Company to host an investor conference call and webcast at 4:30pm EDT
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that the Company will release financial results for the first quarter ended March 31, 2024 on Wednesday, May 15th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operating results.
Participants should dial 1-800-717-1738 (domestic) or 1-646-307-1865 (international).
To access the Call me™ feature, which avoids having to wait for an operator, click .
A live webcast of the conference call will also be available and on the investor relations page of the Company's corporate website at .
After the live webcast, the event will be archived on Eyenovia’s website for one year.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery, which will be launched later this summer.
Eyenovia is also advancing late-stage development of medications in the Optejet device for myopia progression (MicroPine, partnered with Arctic Vision in China and South Korea) and other indications.
For more information, visit .
The Eyenovia Corporate Information slide deck may be found at .
Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
(646) 751-4363
Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
